Loading
Aytu Biopharma, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Jun 2025.
Aytu Biopharma, Inc: what insiders have been doing
Aytu Biopharma, Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 8 insiders have disclosed 8 filings since 18 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Aytu Biopharma, Inc has been absent for the past year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Compared with its exchange (5,458 companies, median 22 filings), a count of 8 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 9 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€219,468
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJoshua R. Disbrow2 buys
Jarrett Disbrow1 buy
Since the insiders bought
- +13.5%Entry US$1.93 · Close at T+365 US$2.19
- +13.5%Entry US$1.93 · Close at T+365 US$2.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Aytu Biopharma, Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$9.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,658 of 24,161 companies
39.1
score / 100
Value46
Quality32
FCF yld15%
Earn yld-64%
EV/EBITDA·
ROE-53%
Gross mgn64%
Net mgn-25%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$2.04
Analyst consensus
3 analystsStrong buy
US$7.00Target US$9.67(+374%)US$15.00
Income statement
RevenueUS$57.6M
Gross profitUS$36.8M64% margin
EBITDA-US$8.4M-15% margin
Net income-US$14.3M-24.8% margin
Valuation
PER (forward)13.2x
P/Book0.6x
Beta0.18
Balance sheet & cash
Market capUS$22.2M
Total debtUS$17M
Free Cash FlowUS$3.3M
Debt / Equity51%
Profitability & ownership
ROE-52.6%
ROA-4.5%
% insiders8.2%
% institutions35.5%
Last declaration on 30 July 2026
Declarations59 total
10,000 shares0Common StockSEC:0001437749-26-025075:0
10,000 shares0Common StockSEC:0001437749-26-025076:0
10,000 shares0Common StockSEC:0001437749-26-025077:0
10,000 shares0Common StockSEC:0001437749-26-025078:0
25,000 shares0Common StockSEC:0001437749-26-025080:0
15,000 shares0Common StockSEC:0001437749-26-025081:0
20,000 shares0Common StockSEC:0001437749-26-025082:0
30,000 shares0Common StockSEC:0001437749-26-025083:0
10,000 shares0Common StockSEC:0001437749-25-030632:0
10,000 shares0Common StockSEC:0001437749-25-030634:0
10,000 shares0Common StockSEC:0001437749-25-030636:0
10,000 shares0Common StockSEC:0001437749-25-030639:0
31,446 shares0Common StockSEC:0001437749-25-030642:0
22,500 shares0Common StockSEC:0001437749-25-030642:1
16,243 shares0Common StockSEC:0001437749-25-030645:0
17,500 shares0Common StockSEC:0001437749-25-030645:1
19,606 shares0Common StockSEC:0001437749-25-030648:0
12,500 shares0Common StockSEC:0001437749-25-030648:1
12,500 shares0Common StockSEC:0001437749-25-030650:0
66,666 shares@ US$1.5042.7% of flowCommon StockSEC:0001437749-25-019956:0
Canonical exit: 7 Sept 2025 (T+90)
16,666 shares@ US$1.50100.0% of flowCommon StockSEC:0001437749-25-019958:0
Canonical exit: 7 Sept 2025 (T+90)
209 sharesCommon SharesSEC:0001437749-25-010224:0
15,000 shares@ US$1.309.2% of flowCommon StockSEC:0001437749-25-005873:0
Canonical exit: 29 May 2025 (T+90)
105 sharesCommon SharesSEC:0000912282-25-000223:0
208 sharesCommon SharesSEC:0000912282-25-000018:0
25 of 59 declarations
About Aytu Biopharma, Inc
Aytu BioPharma, Inc. is a U.S.-based specialty pharmaceutical company listed on the Nasdaq Capital Market in the United States under the ticker AYTU. From an equity analyst perspective, it is best characterized as a small-cap commercial-stage biopharma company that combines branded prescription products with a focused central nervous system (CNS) strategy. The company’s headquarters are in Denver, Colorado. Aytu was originally incorporated as Rosewind Corporation in 2002, later reincorporated in Delaware in 2015, and renamed Aytu BioPharma, Inc. in 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf))
The current strategic narrative is centered on CNS medicines, particularly major depressive disorder (MDD) and ADHD. Aytu’s most important recent growth driver is EXXUA (gepirone) extended-release tablets, a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for adults with MDD. The company emphasizes EXXUA’s differentiated clinical profile, including the absence of a label warning for sexual dysfunction, which may support positioning in a large and highly competitive U.S. antidepressant market. In June 2025, Aytu entered into an exclusive commercialization agreement for EXXUA in the United States and subsequently launched the product as the centerpiece of its commercial strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf))
Read moreShow less
Alongside EXXUA, Aytu retains legacy and supporting product lines that help diversify revenue. Its ADHD portfolio includes Adzenys XR-ODT, indicated for patients six years and older, and Cotempla XR-ODT. The company also commercializes Karbinal, a 12-hour carbinoxamine oral suspension for allergy symptoms, as well as the pediatric fluoride/vitamin prescription brands Poly-Vi-Flor and Tri-Vi-Flor. These products give Aytu a mix of higher-growth CNS assets and more mature pediatric/allergy franchises. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf))
Competitive positioning remains challenging. Aytu operates in therapeutic areas dominated by large branded pharmaceutical competitors and, in several cases, subject to generic pressure. The company has therefore been reshaping its portfolio and focusing capital on commercialization rather than broad clinical development. Recent milestones include the June 2025 equity raise, the EXXUA commercialization transaction, the company’s launch execution in late 2025, and international commercialization arrangements for Adzenys and Cotempla, including Canada. For investors in French-speaking markets, AYTU is a high-risk, catalyst-driven pharmaceutical name whose valuation will likely depend on EXXUA uptake, preservation of legacy product cash flows, and disciplined capital allocation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
